MedTrace Logo

Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)

NCT00000586 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2016-04-14

No results posted yet for this study

Summary

To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.

Conditions

Interventions

DRUG

hydroxyurea

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Samuel Charache · Johns Hopkins University

  • Michael Terrin · Maryland Medical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-01-31
Primary Completion
1994-06-30
Completion
1994-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000586 on ClinicalTrials.gov